The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1β

Experimental Physiology

Volumn 98, Issue 2, 2013, Pages 462-472

  Bracey, Nathan A ^a,b   Beck, Paul L ^a   Muruve, Daniel A ^a   Hirota, Simon A ^a,b   Guo, Jiqing ^b   Jabagi, Habib ^b   Wright, James R ^c   Macdonald, Justin A ^b   Lees Miller, James P ^b   Roach, Daniel ^b   Semeniuk, Lisa M ^b   Duff, Henry J ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b LIBIN CARDIOVASCULAR INSTITUTE OF ALBERTA   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CASPASE; CRYOPYRIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; MESSENGER RNA; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDITIS; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVATION; GENE OVEREXPRESSION; HEART FAILURE; HEART MUSCLE CELL; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; SYSTOLIC DYSFUNCTION;

EID: 84872696318     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2012.068338     Document Type: Article

References (37)

1. Abbate A, Kontos MC, Grizzard JD, Biondi-Zoccai GGL, Van Tassell BW, Robati R et al . (2010). Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol 105, 1371-1377.e1.
2. Abbate A, Salloum FN, Vecile E, Das A, Hoke NN, Straino S et al . (2008). Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 117, 2670-2683.
3. Bauernfeind F, Horvath G, Stutz A, Alnemri ES, Speert D, Fernandes-Alnemri T et al . (2010). Cutting edge: NF-κB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol 183, 787-791.
4. Borja J, Arnáiz E, Izquierdo I & Souto M (2006). Controversies in ventricular remodelling. Lancet 367, 1315-1316.
5. Bujak M & Frangogiannis NG (2009). The role of IL-1 in the pathogenesis of heart disease. Arch Immunol Ther Exp (Warsz.) 57, 165-176.
6. Carter DB, Deibel MRJ, Dunn CJ, Tomich CSC, Laborde AL, Slightom JL et al . (1990). Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature 344, 633-638.
7. Csont T, Viappiani S, Sawicka J, Slee S, Altarejos JY, Batinić-Haberle I et al . (2005). The involvement of superoxide and iNOS-derived NO in cardiac dysfunction induced by pro-inflammatory cytokines. J Mol Cell Cardiol 39, 833-840.
8. Curtis LH, Greiner MA, Hammill BG, Kramer JM, Whellan DJ, Schulman KA et al . (2008). Early and long-term outcomes of heart failure in elderly persons, 2001-2005. Arch Intern Med 168, 2481-2488.
9. 2+ leak from the sarcoplasmic reticulum and susceptibility to arrhythmia in rat ventricular myocytes. Cell Calcium 47, 378-386.
10. González A, Ravassa S, Beaumont J, López B & Díez J (2011). New targets to treat the structural remodeling of the myocardium. J Am Coll Cardiol 58, 1833-1843.
11. Guillén I, Blanes M, Gómez-Lechón MJ & Castell JV (1995). Cytokine signaling during myocardial infarction: sequential appearance of IL-1β and IL-6. Am J Physiol 269, R229-R235.
12. Hedayat M, Mahmoudi MJ, Rose NR & Rezaei N (2010). Proinflammatory cytokines in heart failure: double-edged swords. Heart Fail Rev 15, 543-562.
13. Hirota SA, Ng J, Lueng A, Khajah M, Parhar K, Li Y et al . (2010). NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm Bowel Dis 2, 1-14.
14. Ing DJ, Zang J, Dzau VJ, Webster KA & Bishopric NH (1999). Modulation of cytokine-induced cardiac myocyte apoptosis. Circ Res 84, 21-33.
15. Kalogeropoulos AP, Georgiopoulou VV & Butler J (2012). From risk factors to structural heart disease: the role of inflammation. Heart Fail Clin 8, 113-123.
16. Kawaguchi M, Takahashi M, Hata T, Kashima Y, Usui F, Morimoto H et al . (2011). Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation 123, 594-604.
17. Lecour S & James RW (2011). When are pro-inflammatory cytokines SAFE in heart failure Eur Heart J 32, 680-685.
18. Lim HW, Windt LJD, Steinberg L, Taigen T, Witt SA, Kimball TR et al . (2000). Calcineurin expression, activation, and function in cardiac pressure-overload hypertrophy. Circulation 101, 2431-2437.
19. Luheshi NM, Giles JA, Lopez-Castejon G & Brough D (2012). Sphingosine regulates the NLRP3-inflammasome and IL-1β release from macrophages. Eur J Immunol 42, 716-725.
20. McDonald B, Pittman K, Menezes GB, Hirota SA, Slaba I, Waterhouse CCM et al . (2010). Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 330, 362-366.
21. Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, Roose-Girma M et al . (2006). Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440, 228-232.
22. Martinon F, Burns K & Tschopp J (2002). The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10, 417-26.
23. Martinon F, Gaide O, Pétrilli V, Mayor A & Tschopp J (2007). NALP inflammasomes: a central role in innate immunity. Semin Immunol 29, 213-229.
24. Martinon F, Pétrilli V, Mayor A, Tardivel A & Tschopp J (2006). Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237-241.
25. Merkle S, Frantz S, Schön MP, Bauersachs J, Buitrago M, Frost RJA et al . (2007). A role for caspase-1 in heart failure. Circ Res 100, 645-653.
26. Mezzaroma E, Toldo S, Farkas D, Seropian IM, Van Tassell BW, Salloum FN et al . (2011). The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc Natl Acad Sci USA 108, 2-7.
27. Obasanjo-Blackshire K, Mesquita R, Jabr RI, Molkentin JD, Hart SL, Marber MS et al . (2006). Calcineurin regulates NFAT-dependent iNOS expression and protection of cardiomyocytes: co-operation with Src tyrosine kinase. Cardiovasc Res 71, 672-683.
28. Pétrilli V, Dostert C, Muruve DA & Tschopp J (2007). The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol 19, 615-622.
29. Schroder K, Zhou R & Tschopp J (2010). The NLRP3 inflammasome: a sensor for metabolic danger Science 327, 296-300.
30. Schulz R, Panas DL, Olley M & Lopaschuk GD (1995). The role of nitric oxide in cardiac depression induced by interleukin-1 and tumour necrosis factor-α. Br J Pharmacol 114, 27-34.
31. Semeniuk LM, Severson DL, Kryski AJ, Swirp SL, Molkentin JD & Duff HJ (2003). Time-dependent systolic and diastolic function in mice overexpressing calcineurin. Am J Physiol Heart Circ Physiol 284, H425-430.
32. Shi CS, Shenderov K, Huang NN, Kabat J, Abu-Assab M, Fitzgerald KA et al . (2012). Activation of autophagy by inflammatory signals limits IL-1β production by targeting ubiquitinated inflammasomes for destruction. Nat Immunol 13, 255-263.
33. Somers JR, Beck PL, Lees-Miller JP, Roach D, Li Y, Guo J et al . (2008). iNOS in cardiac myocytes plays a critical role in death in a murine model of hypertrophy induced by calcineurin. Am J Physiol Heart Circ Physiol 295, H1122-H1131.
34. Tatsumi T, Matoba S, Kawahara A & Keira N (2000). Cytokine-induced nitric oxide production inhibits mitochondrial energy production and impairs contractile function in rat cardiac myocytes. J Am Coll Cardiol 35, 1338-1346.
35. Van Tassell BW, Arena RA, Toldo S, Mezzaroma E, Azam T, Seropian IM et al . (2012) Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. PLos One 7, e33438.
36. Vilaysane A, Chun J, Seamone ME, Wang W, Chin R, Hirota S et al . (2010). The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J Am Soc Nephrol 21, 1732-1744.
37. Whelan RS, Kaplinskiy V & Kitsis RN (2010). Cell death in the pathogenesis of heart disease: mechanisms and significance. Annu Rev Physiol 72, 19-44.